11:45 AM
 | 
Dec 05, 2018
 |  BC Extra  |  Financial News

Gates leads Kallyope's $21M B round expansion

Bill Gates has joined an existing investor syndicate to lead a $21 million expansion of a series B round for Kallyope Inc. (New York, N.Y.).

Kallyope has now raised $87 million in the round and $131 million overall as it develops small molecules against undisclosed targets in the gut-brain axis.

The company previously disclosed its lead programs in metabolic disorders, such as obesity and non-alcoholic steatohepatitis (NASH), and neurological diseases including mood disorders and Parkinson’s disease (see "Data-Driven").

Existing investors Lux Capital, The Column Group, Polaris Partners, Illumina Ventures, Alexandria Venture Investments, Euclidean Capital and Two Sigma Investments took part in the expansion.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD